Mesenchymal Stem Cells Treatment for AIDS Patients at Late Stage
ConditionAIDS
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18-65
SponsorCell Energy Life Sciences Group Co. LTD
About this trial
The goal of this study is to conduct a prospective, double-blind, randomized placebo-controlled clinical trial to investigate the safety and efficacy of mesenchymal stem cells treatment for AIDS patients at late stage.
Eligibility criteria
Qualifiers
Confirmed HIV infection, aged 18-65, both genders
CD4+T count less than 500 cells/ul at baseline.
No serious AIDS related events. 3. could understand and sign the informed consent form and comply with the requirements of this study.
Disqualifiers
have HBV/HCV/HDV/HEV infection, and the virological test is positive.
The viral load for CMV and EBV is more than 1000 copies/ML.
have HIV-2 infection.
have serious complications in organs including renal, circulatory, respiratory, digestive, endocrine, neural and immunological diseases and tumors.
Trial design
Treatments tested in this trial
- mesenchymal stem cell
- saline
Treatment groups
150 Participants
are divided into 3 treatment groupsSponsors and collaborators
Cell Energy Life Sciences Group Co. LTD
Lead sponsor
Beijing 302 Hospital
Collaborator
Shenzhen Third People's Hospital
Collaborator
Fifth Hospital of Shijiazhuang City
Collaborator
Beijing YouAn Hospital
Collaborator
Source ClinicalTrials.gov